J Korean Ophthalmol Soc > Volume 58(9); 2017 > Article
Journal of the Korean Ophthalmological Society 2017;58(9):1042-1049.
DOI: https://doi.org/10.3341/jkos.2017.58.9.1042    Published online September 15, 2017.
Fourteen Anti-vascular Endothelial Growth Factor Injections for Age-related Macular Degeneration: Ending Period and Clinical Outcome.
Jae Wook Han, Jong Woo Kim, Chul Gu Kim, Dong Won Lee, Jung Il Han, Young Ju Lew, Jae Hui Kim
Myung-Gok Eye Resarch Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@kimeye.com
나이관련황반변성에 대한 항혈관내피성장인자 14회 유리체내주사: 완료시기와 임상결과
한재욱⋅김종우⋅김철구⋅이동원⋅한정일⋅유영주⋅김재휘
건양대학교 의과대학 김안과병원 안과학교실 명곡안연구소
Correspondence:  Jae Hui Kim,
Email: kjh7997@kimeye.com
Received: 29 June 2017   • Revised: 29 July 2017   • Accepted: 22 August 2017
Abstract
PURPOSE
To evaluate the clinical course of patients who had completed 14 ranibizumab or aflibercept monocular treatments. METHODS: Retrospective medical record analysis was performed to 24 patients who were diagnosed with monocular neovascular age-related macular degeneration and had completed 14 ranibizumab or aflibercept monocular injections, allowed by the Korean National Health Care system. Time to completion was measured along with the percentage and timing of medication switch. Best-corrected visual acuity (BCVA) was measured at the time of diagnosis, after 3-loading injections, and the time of completion. Additionally, we searched for any other factors that had influenced the time to completion. RESULTS: The average time to completion of 14 injections was 32.3 ± 6.2 months (21–48 months). The switching was performed in 17 eyes (70.8%), and it was done after 9.4 ± 2.1 injections (4–14 injections) with prior medication. After 14 injections, the BCVA improved in 6 eyes (25.0%), unchanged in 8 eyes (33.3%), and worsened in 10 eyes (41.7%). Complete resolution of intraretinal fluid and subretinal fluid after 3 loading injections were observed in 20 eyes, and it was significantly related to time to the first recurrence and time to the completion of 14 injections (p = 0.007, r = 0.583). CONCLUSIONS: The average time to completion of 14 injections was 32.3 months, and switching of medication was performed in 70.8%. Longer time to the first recurrence was related to longer completion time. This study will provide useful facts when informing the patients their future treatment plans under the Korean Health Care system.
Key Words: Aflibercept;Choroidal neovascularization;Macular degeneration;Ranibizumab


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next